Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1

Resistance to docetaxel is a key problem in current prostate cancer management. Sphingosine kinase 1 (SK1) and phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways have been implicated in prostate cancer chemoresistance. Here we investigated whether their combined targe...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Alshaker, Heba, Wang, Qi, Kawano, Yoshiaki, Arafat, Tawfiq, Böhler, Torsten, Winkler, Mathias, Cooper, Colin, Pchejetski, Dmitri
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2016
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5348367/
https://ncbi.nlm.nih.gov/pubmed/27821815
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13115
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky